Search hospitals > Michigan > Grand Rapids

START Midwest

Claim this profile
Grand Rapids, Michigan 49546
Global Leader in Solid Tumors
Global Leader in Uterine Tumors
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lung Cancer
Conducts research for Cancer
113 reported clinical trials
6 medical researchers
Photo of START Midwest in Grand RapidsPhoto of START Midwest in Grand RapidsPhoto of START Midwest in Grand Rapids

Summary

START Midwest is a medical facility located in Grand Rapids, Michigan. This center is recognized for care of Solid Tumors, Uterine Tumors, Non-Small Cell Lung Cancer, Lung Cancer, Cancer and other specialties. START Midwest is involved with conducting 113 clinical trials across 174 conditions. There are 6 research doctors associated with this hospital, such as Nehal Lakhani, MD, Manish Sharma, MD, Katie Robinson, MD, and Sreenivasa Chandana, M.D., Ph.D..

Area of expertise

1Solid Tumors
Global Leader
START Midwest has run 87 trials for Solid Tumors. Some of their research focus areas include:
Stage IV
Stage III
KRAS positive
2Uterine Tumors
Global Leader
START Midwest has run 74 trials for Uterine Tumors. Some of their research focus areas include:
Stage IV
Stage III
KRAS positive

Top PIs

Clinical Trials running at START Midwest

Solid Tumors
Uterine Tumors
Non-Small Cell Lung Cancer
Ovarian Cancer
Lung Cancer
Colorectal Cancer
Skin Cancer
Breast Cancer
Cancer
Pancreatic Cancer
Image of trial facility.

Zotatifin

for Solid Tumors

This trial is testing a new drug called Zotatifin for patients with advanced cancers that haven't improved with standard treatments. The drug works by stopping cancer cells from making essential proteins, which may slow or stop the cancer.
Recruiting3 awards Phase 1 & 221 criteria
Image of trial facility.

AU-007

for Advanced Cancer

This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w). Once the recommended phase 2 dose (RP2D) of AU-007 plus aldesleukin was determined, (AU-007 Q2w plus a single loading dose of aldesleukin), AU-007 plus aldesleukin is also being administered with avelumab or nivolumab.
Recruiting1 award Phase 1 & 28 criteria
Image of trial facility.

ART6043

for Metastatic Cancer

This trial tests a new cancer drug, ART6043, alone or with other drugs (Olaparib and Niraparib) in patients with advanced cancers that have genetic defects in DNA repair. The treatment aims to exploit the cancer cells' inability to fix their DNA, making it harder for them to survive. Olaparib is used to treat certain cancers by preventing the cancer cells from fixing their DNA, which makes it harder for them to survive.
Recruiting1 award Phase 1 & 2

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at START Midwest?
START Midwest is a medical facility located in Grand Rapids, Michigan. This center is recognized for care of Solid Tumors, Uterine Tumors, Non-Small Cell Lung Cancer, Lung Cancer, Cancer and other specialties. START Midwest is involved with conducting 113 clinical trials across 174 conditions. There are 6 research doctors associated with this hospital, such as Nehal Lakhani, MD, Manish Sharma, MD, Katie Robinson, MD, and Sreenivasa Chandana, M.D., Ph.D..
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security